Literature DB >> 15067206

The inhibition of apoptosis in EL4 lymphoma cells overexpressing growth hormone.

Robyn E Arnold1, Douglas A Weigent.   

Abstract

The antiapoptotic action of exogenous growth hormone (GH) has been reported for several lymphoid cell lines; however, the potential role of endogenous GH in apoptosis has not been thoroughly investigated. This study was designed to investigate the effects of endogenous GH on apoptosis induced by methyl methanesulfonate (MMS) in a T cell lymphoma overexpressing GH (GHo). The results of these experiments have shown that in EL4 lymphoma cells, overexpression of GH sustained viability after exposure to MMS compared to control cells. The extent of DNA fragmentation measured by ladder formation on agarose gels was reduced in GHo cells following treatment with MMS, when compared to control cells. Adding exogenous GH to control cells and treatment of GHo cells with antibodies to GH had no effect on MMS-induced DNA ladder formation. In further studies, DNA microarray analysis suggested a marked decrease in the constitutive expression of bax, BAD, and caspases 3, 8, and 9 in GHo cells compared to controls. In addition, after treatment with MMS, the activities of caspases 2, 3, 6, 8, and 9 were all lower than control in GHo cells. Western blot analysis detected an increase in Bcl-2 while the levels of nuclear factor kappa B (NFkappaB) remained unchanged in GHo cells. Treatment of EL4 cells with antisense deoxyoligonucleotides to GH and specific inhibitors of NFkappaB (SN-50) increased DNA fragmentation. GHo cells show increased levels of phosphorylated Akt and GSK-3, suggesting inactivation of this proapoptotic protein. The results, taken together with our previous data which showed increased nitric oxide formation in GHo cells, suggest a possible mechanism for the antiapoptotic effects of endogenous GH through the production of nitric oxide and support the idea that endogenous GH may play an important role in the survival of lymphocytes exposed to stressful stimuli. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067206     DOI: 10.1159/000076764

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  14 in total

Review 1.  Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways.

Authors:  Dennis D Taub; William J Murphy; Dan L Longo
Journal:  Curr Opin Pharmacol       Date:  2010-06-04       Impact factor: 5.547

Review 2.  Extrapituitary growth hormone.

Authors:  S Harvey
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

3.  High molecular weight isoforms of growth hormone in cells of the immune system.

Authors:  Douglas A Weigent
Journal:  Cell Immunol       Date:  2011-06-12       Impact factor: 4.868

Review 4.  Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer.

Authors:  John J Kopchick; Reetobrata Basu; Darlene E Berryman; Jens O L Jorgensen; Gudmundur Johannsson; Vishwajeet Puri
Journal:  Nat Rev Endocrinol       Date:  2022-06-24       Impact factor: 47.564

5.  Growth hormone-dependent changes in the rat lung proteome during alveorization.

Authors:  J A Beyea; D M Olson; S Harvey
Journal:  Mol Cell Biochem       Date:  2008-11-05       Impact factor: 3.396

6.  Expression of lymphocyte-derived growth hormone (GH) and GH-releasing hormone receptors in aging rats.

Authors:  Douglas A Weigent
Journal:  Cell Immunol       Date:  2013-05-03       Impact factor: 4.868

Review 7.  Neuroendocrine hormones such as growth hormone and prolactin are integral members of the immunological cytokine network.

Authors:  Doug Redelman; Lisbeth A Welniak; Dennis Taub; William J Murphy
Journal:  Cell Immunol       Date:  2008-03-04       Impact factor: 4.868

8.  Hypoxia and cytoplasmic alkalinization upregulate growth hormone expression in lymphocytes.

Authors:  Douglas A Weigent
Journal:  Cell Immunol       Date:  2013-04-11       Impact factor: 4.868

9.  Growth hormone is a cellular senescence target in pituitary and nonpituitary cells.

Authors:  Vera Chesnokova; Cuiqi Zhou; Anat Ben-Shlomo; Svetlana Zonis; Yuji Tani; Song-Guang Ren; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-12       Impact factor: 11.205

Review 10.  Dual Characters of GH-IGF1 Signaling Pathways in Radiotherapy and Post-radiotherapy Repair of Cancers.

Authors:  Yunyun Cheng; Wanqiao Li; Ruirui Gui; Chunli Wang; Jie Song; Zhaoguo Wang; Xue Wang; Yannan Shen; Zhicheng Wang; Linlin Hao
Journal:  Front Cell Dev Biol       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.